

FOR IMMEDIATE RELEASE

Company Name Kyowa Kirin Co., Ltd.
Representative Masashi Miyamoto, President and CEO
(Code: 4151, Prime Section of TSE)
Inquiries Satoko Yoshida, Director,
Corporate Communications Department
Media Contact: +81-3-5205-7205
Investor Contact: +81-3-5205-7206

(Collection) "Appendix to the Consolidated Financial Summary Fiscal 2023 Third Quarter"

Tokyo, November 14, 2023 – Kyowa Kirin Co., Ltd. (hereinafter, “Kyowa Kirin”) hereby announces that, the following corrections have been made to some of the statements in the "Appendix to the Consolidated Financial Summary Fiscal 2023 Third Quarter" announced on November 1, 2023.

1. Reason for corrections

This is to correct an error in "Revenue of three global strategic products" on page 5 of the "Appendix to the Consolidated Financial Summary Fiscal 2023 Third Quarter".

2. Details of corrections

Corrections are underlined on the next page.

End

【Before Correction】

III. Revenue from Main Products

Revenue of three global strategic products

<Accumulative>

Unit: Billions of yen

Product name	FY 2022 results				FY 2023 results				FY 2023 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Change amount	Jan - Dec	Progress
Crysvita	24.2	53.5	85.1	127.1	29.4	66.7	103.1	18.0	149.1	69%
Japan	2.0	4.1	6.4	8.9	2.3	4.8	7.4	1.0	11.1	67%
North America	15.8	35.9	57.4	87.0	18.8	46.0	70.2	12.8		
[Millions of USD]	139	298	456	662	143	344	530	74		
EMEA	6.3	13.5	21.2	31.0	8.0	15.3	24.5	3.2	138.0	69%
[Millions of GBP]	41	85	133	192	50	93	151	18		
APAC	0.0	0.1	0.1	0.3	0.3	0.6	1.1	0.9		
Poteligeo	4.7	11.3	17.5	24.2	6.3	13.4	21.3	3.8	29.5	72%
Japan	0.5	1.0	1.5	2.0	0.4	0.9	1.4	(0.0)	2.0	73%
North America	3.3	8.1	12.6	17.2	4.3	9.4	15.1	2.5	19.4	78%
[Millions of USD]	29	67	100	132	33	70	114	14	149	
EMEA	0.9	2.1	3.5	5.1	1.5	3.1	4.8	1.3	8.0	61%
[Millions of GBP]	6	14	22	32	9	19	30	8	50	
APAC	-	-	-	-	-	-	0.0	0.0	-	-
Nourias/Nourianz	2.9	6.5	10.3	14.5	3.3	7.2	11.0	0.7	15.1	73%
Japan	1.8	3.9	5.9	8.0	1.7	3.7	5.5	(0.3)	7.5	73%
North America	1.1	2.6	4.5	6.5	1.7	3.5	5.5	1.0	7.5	73%
Total of three global	31.8	71.3	113.0	165.8	39.0	87.3	135.5	22.5	193.6	70%

<Quarterly>

Unit: Billions of yen

Product name	FY 2022 results				FY 2023 results			
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Jul - Sep	Change amount
Crysvita	24.2	29.4	31.6	42.0	29.4	37.3	36.4	4.8
Japan	2.0	2.2	2.3	2.5	2.3	2.5	2.6	0.3
North America	15.8	20.0	21.5	29.6	18.8	27.2	24.1	2.6
[Millions of USD]	139	159	158	206	143	202	186	28
EMEA	6.3	7.1	7.8	9.7	8.0	7.3	9.2	1.4
[Millions of GBP]	41	44	47	59	50	43	57	10
APAC	0.0	0.0	0.1	0.2	0.3	0.3	0.5	0.4
Poteligeo	4.7	6.6	6.3	6.7	6.3	7.1	8.0	1.7
Japan	0.5	0.5	0.5	0.5	0.4	0.5	0.5	0.0
North America	3.3	4.8	4.4	4.6	4.3	5.1	5.7	1.3
[Millions of USD]	29	38	33	32	33	37	44	11
EMEA	0.9	1.2	1.4	1.6	1.5	1.6	1.8	0.4
[Millions of GBP]	6	8	8	10	9	9	11	3
APAC	-	-	-	-	-	-	0.0	0.0
Nourias/Nourianz	2.9	3.6	3.9	4.1	3.3	3.9	3.8	(0.0)
Japan	1.8	2.1	2.0	2.1	1.7	2.0	1.9	(0.1)
North America	1.1	1.4	1.9	2.0	1.7	1.9	2.0	0.1
Total of three global	31.8	39.5	41.7	52.8	39.0	48.3	48.2	6.5

* Revenue is classified based on consolidated revenue from regional control functions.

* The revenue, generated in various currencies inside each corporate region, is converted and aggregated in USD for North America and in GBP for EMEA.

[After Correction]

III. Revenue from Main Products

Revenue of three global strategic products

<Accumulative>

Unit: Billions of yen

Product name	FY 2022 results				FY 2023 results				FY 2023 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Change amount	Jan - Dec	Progress
Crysvita	24.2	53.5	85.1	127.1	29.4	66.7	103.1	18.0	149.1	69%
Japan	2.0	4.1	6.4	8.9	2.3	4.8	7.4	1.0	11.1	67%
North America	15.8	35.9	57.4	87.0	18.8	46.0	70.2	12.8	138.0	69%
[Millions of USD]	139	298	456	662	143	344	512	56		
EMEA	6.3	13.5	21.2	31.0	8.0	15.3	24.5	3.2		
[Millions of GBP]	41	85	133	192	50	93	144	11		
APAC	0.0	0.1	0.1	0.3	0.3	0.6	1.1	0.9		
Poteligeo	4.7	11.3	17.5	24.2	6.3	13.4	21.3	3.8	29.5	72%
Japan	0.5	1.0	1.5	2.0	0.4	0.9	1.4	(0.0)	2.0	73%
North America	3.3	8.1	12.6	17.2	4.3	9.4	15.1	2.5	19.4	78%
[Millions of USD]	29	67	100	132	33	70	110	10	149	
EMEA	0.9	2.1	3.5	5.1	1.5	3.1	4.8	1.3	8.0	61%
[Millions of GBP]	6	14	22	32	9	19	28	6	50	
APAC	-	-	-	-	-	-	0.0	0.0	-	-
Nourias/Nourianz	2.9	6.5	10.3	14.5	3.3	7.2	11.0	0.7	15.1	73%
Japan	1.8	3.9	5.9	8.0	1.7	3.7	5.5	(0.3)	7.5	73%
North America	1.1	2.6	4.5	6.5	1.7	3.5	5.5	1.0	7.5	73%
Total of three global	31.8	71.3	113.0	165.8	39.0	87.3	135.5	22.5	193.6	70%

<Quarterly>

Unit: Billions of yen

Product name	FY 2022 results				FY 2023 results			
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Jul - Sep	Change amount
Crysvita	24.2	29.4	31.6	42.0	29.4	37.3	36.4	4.8
Japan	2.0	2.2	2.3	2.5	2.3	2.5	2.6	0.3
North America	15.8	20.0	21.5	29.6	18.8	27.2	24.1	2.6
[Millions of USD]	139	159	158	206	143	202	168	9
EMEA	6.3	7.1	7.8	9.7	8.0	7.3	9.2	1.4
[Millions of GBP]	41	44	47	59	50	43	50	3
APAC	0.0	0.0	0.1	0.2	0.3	0.3	0.5	0.4
Poteligeo	4.7	6.6	6.3	6.7	6.3	7.1	8.0	1.7
Japan	0.5	0.5	0.5	0.5	0.4	0.5	0.5	0.0
North America	3.3	4.8	4.4	4.6	4.3	5.1	5.7	1.3
[Millions of USD]	29	38	33	32	33	37	39	7
EMEA	0.9	1.2	1.4	1.6	1.5	1.6	1.8	0.4
[Millions of GBP]	6	8	8	10	9	9	10	1
APAC	-	-	-	-	-	-	0.0	0.0
Nourias/Nourianz	2.9	3.6	3.9	4.1	3.3	3.9	3.8	(0.0)
Japan	1.8	2.1	2.0	2.1	1.7	2.0	1.9	(0.1)
North America	1.1	1.4	1.9	2.0	1.7	1.9	2.0	0.1
Total of three global	31.8	39.5	41.7	52.8	39.0	48.3	48.2	6.5

* Revenue is classified based on consolidated revenue from regional control functions.

* The revenue, generated in various currencies inside each corporate region, is converted and aggregated in USD for North America and in GBP for EMEA.